Amber Warren, | |
683 Blueberry Dr Apt A, Ketchikan, AK 99901-9533 | |
(907) 225-7825 | |
Not Available |
Full Name | Amber Warren |
---|---|
Gender | Female |
Speciality | Community Health Worker |
Location | 683 Blueberry Dr Apt A, Ketchikan, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063018596 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
172V00000X | Community Health Worker | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Amber Warren, 721 Stedman St, Ketchikan, AK 99901-6632 Ph: (907) 225-7825 | Amber Warren, 683 Blueberry Dr Apt A, Ketchikan, AK 99901-9533 Ph: (907) 225-7825 |
News Archive
Not only that; we have also been awarded the Queen's Award for Enterprise: International Trade in recognition of our outstanding international growth. Meaning we are one of only a handful of businesses who have won multiple awards this year.
A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.
Neurons that regularly remodel are more prone to Alzheimer's disease and die when that remodeling goes awry, a new study suggests. The work is the first to track the progression of Alzheimer's at the genetic and molecular levels within neurons vulnerable to the disease.
New research suggests Syrian golden hamsters could be a potentially useful preclinical model for testing vaccine immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.17 and B.1.351 variant.
Misonix, Inc., a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today reported financial results for the six-months and the second quarter of fiscal year 2013, ended December 31, 2012.
› Verified 8 days ago